BridgeMD
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
EU CTIS ID: 2022-502994-40-00
What this study is testing
Phase 2a: To evaluate the efficacy of LY3871801 compared to placebo as measured by changes in DAS28-hsCRP Phase 2b: To evaluate the efficacy of LY3871801 compared to placebo in achieving ACR50
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have a diagnosis of adult onset rheumatoid arthritis for at least 3 months
You likely can't join if
- Had cancer within the last 5 years, except for some types of skin cancer or cervical cancer
- Had certain types of infections within the last 3 months
- Have HIV
- Have current hepatitis virus B or C infection
The study team makes the final eligibility decision.
Where it's taking place
- Mexico
- United States
- India
- United Kingdom
- Argentina
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mexico; United States; India; United Kingdom; Argentina. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.